Inclusion Criteria:

-

- Has provided written informed consent prior to any study-related procedures

- Has been enrolled and treated in Study 2-55-52030-726 and either:

1. Was stable at 96 weeks of treatment or

2. Has received at least one injection in Study 2-55-52030-726 and had a disease
progression and was in the placebo arm

- Has a World Health Organisation (WHO) performance score lower than or equal to 2

Exclusion Criteria:

- Has been enrolled and treated in the frame of the 2-55-52030-726 protocol and had a
disease progression when receiving lanreotide Autogel 120mg

- Has received any new treatment for the entero-pancreatic neuroendocrine tumour since
the end of participation in the 2-55-52030-726 study

- Is likely to require any additional concomitant treatment to lanreotide Autogel 120mg
for the entero-pancreatic neuro-endocrine tumour

- Has a history of hypersensitivity to drugs with a similar chemical structure to
lanreotide Autogel 120mg

- Has been treated with radionuclide at any time prior to study entry